Moderna, Inc. (BMV:MRNA)
Mexico · Delayed Price · Currency is MXN | Market Cap | 938.41B +413.5% |
| Revenue (ttm) | 38.93B -27.6% |
| Net Income | -55.06B |
| EPS | -139.92 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 342 |
| Open | 2,390.00 |
| Previous Close | 2,341.00 |
| Day's Range | 2,325.00 - 2,445.00 |
| 52-Week Range | 414.00 - 2,975.59 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna upgraded to Buy at Argus after FDA approval for updated Covid vaccines
As previously reported, Argus upgraded Moderna (MRNA) to Buy from Hold with an $180 price target following the company’s announcement of FDA approval for updated 2026-2027 COVID-19 vaccines. Moderna n...
Moderna prices upsized $2.6B offering of convertible senior notes due 2032
Moderna (MRNA) announced the pricing of $2.6B aggregate principal amount of 0.00% Convertible Senior Notes due 2032 in a private placement only to persons reasonably believed to be “qualified institut...
Moderna upgraded to Buy from Hold at Argus
Argus upgraded Moderna (MRNA) to Buy from Hold with an $180 price target
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna has also purchased a hedge overl...
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Stephane Bancel, CEO of Moderna , was at a Lebanese restaurant celebrating a friend's birthday late on August 13 when he got the call.
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Moderna receives FDA approval for updated 2026-2027 COVID-19 vaccines
Moderna (MRNA) announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for the 2026-2027 formulas for Spikevax and mNEXSPIKE, containing the J...
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applica...
Moderna Stock (MRNA) Slides 3% on Plans for a $2B Private Placement
Moderna stock was down on Thursday after the company revealed private placement plans that include an offer for $2 billion of convertible senior notes.
Moderna down 6% to $141.10 after $2B convertible note offering
07:31 EDT Moderna (MRNA) down 6% to $141.10 after $2B convertible note offering
Moderna to offer $2B of Convertible Senior Notes due 2032
Moderna (MRNA) announced that it intends to offer, subject to market conditions and other factors, $2B aggregate principal amount of Convertible Senior Notes due 2032 in a private placement only…
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna will also purchase a hedge overl...
Was Moderna Stock's 440% Surge Hiding In Plain Sight?
This article was written by Doug Nathman, with research by his team at Trefis.
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
Moderna Stock (MRNA) Rises 12.5% Today Following Phase 3 mRNA Cancer Vaccine Win with Merck
Biotech firm Moderna ($MRNA) saw its stock rise 12.5% today, building on a multi-day rally after releasing positive Phase 3 trial data for its personalized mRNA cancer vaccine. Developed alongside…
What Happens if Moderna's Cancer Vaccine Works
Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.
Moderna CEO warns China is investing heavily in mRNA as Beijing challenges US in biotechnology
Moderna's 177% stock surge followed its mRNA cancer vaccine success, but CEO Stéphane Bancel says China's biotechnology investments pose a threat.
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
Moderna Is Betting Big on Its Cancer Vaccine. This Is What Wall Street Wants to See.
Moderna's management sees significant long-term potential in intismeran autogene, Barclays says.
Heard on the Street: Moderna's mRNA cancer vaccine marks a major leap in personalized oncology. But the financial math is sobering.
Personalized mRNA shots may prove neither as wide-reaching nor as lucrative as hoped.
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
After years of layoffs, cash burn and political attacks on its core technology, Moderna's melanoma vaccine data notched the biotech company a much-needed win.